8 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2035. from the record
Of the 4 now held by other companies, 4 name Windtree Therapeutics Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2035
Next term end
6
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2035 · High confidence
Also notable
Ends Feb 2035 · High confidence
Also notable
Ends Nov 2035 · High confidence
Molecules for Administration to ROS1 Mutant Cancer Cells
US 10,231,965
The most cited patent in this portfolio, cited by 74 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2035.
Methods for Treating Neuroblastoma
US 10,561,651
Cited by 10 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2035.
Combinations for the Treatment of Neuroblastoma
US 10,085,979
Cited by 14 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Formerly held, still cited
Notable
Ends Dec 2032 · High confidence
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2032.
now held by Windtree Therapeutics, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 23, 2027The maintenance fee for Combinations for the Treatment of Neuroblastoma (US 10,357,490) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 1 fee due Mar 3, 2027The maintenance fee for Pharmaceutical Compositions and Dosage Forms (US 10,398,693) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Methods for Treating Neuroblastoma (US 10,561,651) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Combinations for the Treatment of Neuroblastoma | 2 in force | to Nov 2035 |
| Molecules for Administration to ROS1 Mutant Cancer Cells | 2 in force | to Feb 2035 |
| Pharmaceutical Compositions and Dosage Forms (2020) | 1 in force | to Oct 2038 |
| Pharmaceutical Compositions and Dosage Forms (2020) | 1 in force | to Jul 2038 |
| Methods for Treating Neuroblastoma | 1 in force | to Feb 2035 |
Patents held now
Soonest term end first.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,231,965 | Molecules for Administration to ROS1 Mutant Cancer Cells In force · High confidence | In force | High confidence | |
| US 10,682,348 | Molecules for Administration to ROS1 Mutant Cancer Cells In force · High confidence | In force | High confidence | |
| US 10,561,651 | Methods for Treating Neuroblastoma In force · High confidence | In force | High confidence | |
| US 10,085,979 | Combinations for the Treatment of Neuroblastoma In force · High confidence | In force | High confidence | |
| US 10,357,490 | Combinations for the Treatment of Neuroblastoma In force · High confidence | In force | High confidence | |
| US 10,398,693 | Pharmaceutical Compositions and Dosage Forms In force · High confidence | In force | High confidence | |
| US 11,253,515 | Pharmaceutical Compositions and Dosage Forms In force · High confidence | In force | High confidence | |
| US 11,007,191 | Pharmaceutical Compositions and Dosage Forms In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 4 patents in force now held by others · 17 patents ended · 13 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.